Domestic Biopharma Sovereignty: Vietnam’s Pharmaceutical Market Reaches $7 Billion, Ministry of Health Prioritizes High-Tech Manufacturing and Regulatory Restructuring

Key Development

Speaking at the 30th Anniversary Ceremony of the Drug Administration of Vietnam (Ministry of Health) on August 7, 2026, Minister of Health Dao Hong Lan officially confirmed that Vietnam’s pharmaceutical market has expanded to approximately $7 billion, with annual growth projected at 10% to 15%.

The milestone highlights three decades of regulatory standardization, marking notable expansion across domestic manufacturing capabilities:

• Domestic Market Share: Domestically produced pharmaceuticals currently satisfy 60% of total utilization volume and account for 46% of total pharmaceutical expenditure nationwide.

• Manufacturing Infrastructure: Vietnam currently operates 245 pharmaceutical manufacturing facilities, with 26 facilities holding EU-GMP certifications or equivalent standards—establishing a foundation for advanced formulation technologies and prospective export expansion.

Why It Matters

• Strategic Vulnerabilities Facing Domestic Manufacturing: Despite reaching a $7 billion valuation, Minister Dao Hong Lan highlighted core structural challenges:

  1. Upstream API Dependency: Domestic R&D capacity for novel active pharmaceutical ingredients (APIs) remains constrained; domestic manufacturing continues to rely heavily on imported raw materials, specialized formulation technologies, and imported specialty biopharmas.

  2. Fragmented Enterprise Scale: Industrial chemical-pharmaceutical processing remains underdeveloped; global supply chain integration remains limited relative to market potential.

  3. Disruption from AI & Precision Medicine: Rapid advancements in biotechnology, artificial intelligence (AI), Big Data, and precision medicine are transforming global drug discovery and manufacturing workflows.

• Six Core Mandates for Industry Sovereignty: To secure national drug supply security and industrial self-reliance, the Ministry of Health directed the Drug Administration of Vietnam to execute six priority mandates:

  1. Modernize legal frameworks, centered on comprehensive amendments to the Pharmaceutical Law.

  2. Ensure uninterrupted supply of high-quality medicines at transparent prices; integrate IT tracking for supply traceability.

  3. Execute the National Strategy for Pharmaceutical Industry Development through 2030 (Vision 2045); incentivize technology transfer for biologics, rare disease drugs, and advanced formulations.

  4. Strengthen post-market surveillance, pharmacovigilance, price transparency, and counterfeit drug prevention.

  5. Digitulate national distribution tracking networks via shared data repositories.

  6. Expand specialized clinical pharmacy and regulatory management training.

Healthcare Insight Analysis

From the perspective of Healthcare Insight, the directives issued by Minister Dao Hong Lan on August 7, 2026, mark a strategic shift: Strategic Pivot to Biopharma Sovereignty.

Vietnam’s pharmaceutical landscape is encountering an inflection point. Capturing 60% of market volume while generating only 46% of total market value underscores that domestic production remains concentrated within low-margin generic categories (Group 3 and Group 4 hospital tenders). Conversely, innovator drugs, biologics, and complex oncology regimens accounting for over 50% of healthcare expenditure remain dominated by multinational corporations.

To enhance national self-reliance, Vietnam must address two structural priorities:

1. Institutional Legislative Reform (Amended Pharmaceutical Law): Establishing targeted regulatory incentives, accelerated marketing authorization renewals, and preferential public insurance (VHI) tender scoring for EU-GMP/US-FDA certified facilities executing local technology transfers for originative molecules.

2. Building a Domestic Biosimilars & R&D Ecosystem: Encouraging joint ventures between global Big Pharma and leading domestic manufacturers (e.g., DHG Pharma, Traphaco, Imexpharm) to produce next-generation biologics locally, insulating the national healthcare system from geopolitical or supply chain disruptions.

Market Implications

1. Accelerating Facility Upgrades to EU-GMP Standards: Existing manufacturers will accelerate capital expenditure toward EU-GMP certification to compete effectively within high-tier hospital tender channels (ETC).

2. Expansion of M&A and Technology Transfer Deals: Multinational pharmaceutical companies will expand strategic partnerships and technology transfers with domestic manufacturers to capitalize on preferential government procurement policies.

3. Sustained Investment Capital Inflows: A 10%–15% annual growth rate across a $7 billion market will continue to attract private equity (PE) and foreign institutional capital into Vietnam’s manufacturing and retail pharmacy sectors.

Performance Ledger: Vietnam Pharmaceutical Market Metrics (August 2026)

Development Indicator	Recorded Benchmark (2026)	Strategic Rationale & Targets
Market Valuation	~ $7.0 Billion (10-15% annual CAGR)	Fast-growing healthcare consumption market in SEA.
Domestic Share (Volume)	60% of total volume utilized	Secures self-reliance in primary care essential medicines.
Domestic Share (Value)	46% of total value spent	Requires upgrading value-share via high-tech biopharmas.
Manufacturing Base	245 units (26 facilities EU-GMP certified)	Standardizing production; enabling tech-transfer & exports.
Legislative Focus	Comprehensive Pharmaceutical Law Revision	Streamlining admin procedures, attracting FDI & price controls.

Source: https://baochinhphu.vn/thi-truong-duoc-pham-dat-7-ty-usd-nganh-duoc-huong-toi-nang-cao-nang-luc-tu-chu-102260807184211842.htm